Welcome to our dedicated page for Trevena SEC filings (Ticker: TRVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trevena, Inc. filings document material agreements, securities status, and capital-structure disclosures for a CNS-focused biopharmaceutical issuer. The record identifies the company's common stock under TRVN on the OTC Expert Market and includes Form 8-K disclosure of an assignment and release agreement affecting obligations under a royalty-based loan agreement originally entered into in 2022 and amended in 2024.
Company filings also provide formal context for Trevena's Delaware corporate status, material definitive agreements, reporting obligations, operating entities, and royalty-financing arrangements.
Trevena, Inc. entered into an Assignment and Release Agreement under which its lender agreed to terminate and release the company from all obligations under a royalty-based loan agreement, except for indemnification and other obligations that already survive termination under that loan’s existing terms. In return, Trevena agreed to transfer all of its rights, title, and interest in its Chinese License Agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd. for royalties in the China territory. Trevena will retain only the rights to commercialization milestone payments under that Chinese license.